Navigation Links
PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
Date:6/26/2008

HUNDREDS OF CUSTOMER HOSPITALS USING ELECTRONIC 222 TO ORDER CLASS II

CONTROLLED SUBSTANCES

SEATTLE, June 9 /PRNewswire/ -- PharMEDium Services, LLC, the leading provider of outsourced hospital pharmacy I.V. compounded solutions, has expanded its first-in-the-industry electronic 222 (e-222) ordering initiative, which enables virtually real-time ordering of Schedule II Controlled Substances versus the more time-consuming traditional process, to all hospitals nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051202/PHARMEDIUMLOGO)

The company announced the initiative at the American Society of Health-System Pharmacists' Summer Meeting and exhibition here.

Hundreds of customers are now ordering pain management medications through PharMEDium's e-222 system, which applies to the entire line of its pain management services. "Our expansion of e-222 represents an ongoing commitment to patient safety, quality, and superior customer service. The early and fast adoption by our customers represents their partnership with us in helping make e-222 a standard practice across our industry," said David Jonas, PharMEDium's Chairman and Chief Executive Officer.

PharMEDium's new controlled substance ordering system aligns with the efforts of the U.S. Drug Enforcement Administration (DEA) and drug industry leaders to take advantage of e-commerce tools to improve efficiency and effectiveness associated with controlled substances ordering. DEA requires a Form 222 for all orders of Schedule II Controlled Substances, which until recently could only be processed through paper forms. E-222 ordering takes about 20 seconds, versus about 20 minutes for paper orders, according to DEA's Office of Diversion Control (ODC). In addition, the elimination of the paper Form 222 reduces the time it takes to receive an order by one to two days. Hospitals interested in e-222 must obtain a digital certificate from the DEA to participate, which typically takes 30 days from application to approval.

"E-222 ordering has significant benefits," said Susan Groth, Pharmacy Buyer at Methodist Hospital in St. Louis Park, MN. "This initiative makes the ordering process faster and easier, in addition to reducing errors and rework," Groth added.

"E-222 is one element of PharMEDium's online customer service offering available on the company's website," Jonas said. "In addition to online ordering, PharMEDium's customers can obtain order status information, track shipments, and review invoice history at pharmedium.com. These value-added features were developed based on extensive customer feedback and provide a multitude of time- and resource-saving benefits. PharMEDium is committed to deploying new and innovative online functionality to provide our customers with world-class customer service," Jonas added.

About PharMEDium Services, LLC

For more than 15 years, PharMEDium has been the leading provider of outsourced compounding services. In that time, PharMEDium has grown into a nationwide network of state licensed and federally registered compounding centers providing trusted solutions to more than 1,800 hospitals throughout the United States. Managed by licensed pharmacists and staffed by certified technicians, the company complies with all applicable state laws and FDA regulations, including USP Chapter < 797 > and DEA requirements.

Contact: Amy Langan, MEDIA INQUIRIES: Jon Ross,

PharMEDium Director of Marketing Ross Consulting &

847/457-2327 Communications

Email: info@pharmedium.com 773-271-0677

jross1chi@prodigy.net


'/>"/>
SOURCE PharMEDium Services, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology news :

1. March of Dimes announces Prematurity Campaign expansion at Surgeon Generals conference
2. TAU announces new supercenter for renewable energy
3. Ecological Society of America announces its 93rd Annual Meeting
4. Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems
5. BIO-key(R) Announces First Quarter 2008 Earnings Release and Conference Call Schedule
6. Autism Speaks announces multinational initiative
7. Aware Announces Q1 2008 Earnings Conference Call
8. The Alliance for Lupus Research announces 2008 grantees
9. Titanium Group Announces Contract for Security Solution in High-End Residentials
10. National Lung Cancer Partnership announces winner of 2007 Career Development Award
11. BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... 7, 2016 According to a new market research report ... (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - Global ... from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at ... Continue Reading ... MarketsandMarkets Logo ...
(Date:12/7/2016)...   Veridium , a leader in biometrics-based ... CEO James Stickland . Stickland, a seasoned ... has served in senior executive roles for HSBC, ... expanding a pipeline of venture capital and accelerating ... served as managing director of U.K.-based fintech firm ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... ... short response times capable of performing routine electrochemical biosensing has increased dramatically. ... provide fast, sensitive detection and quantification of various analytes in complex samples. ...
(Date:1/12/2017)... Conn. , Jan. 12, 2017   ... company and maker of Flublok Influenza Vaccine ... Zika vaccine candidate had good safety results and ... in preclinical studies. The product is expected to ... few months.  In addition, the Institute of Technology ...
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
(Date:1/11/2017)...  Brian Mehling, M.D., world-renowned stem cell researcher, board-certified ... (BHI), will be attending the 47th Annual World Economic ... January 17-20, 2017. This will be Dr. Mehling,s fifth ... of this year,s forum is Responsive and Responsible Leadership; ... strategies for fostering greater social inclusion and human development. ...
Breaking Biology Technology: